Have a feature idea you'd love to see implemented?
Let us know!
ALRN Aileron Therapeutics Inc
Price (delayed)
$3.72
Market cap
$80.6M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.28
Enterprise value
$58.65M
Aileron Therapeutics Inc. is a clinical-stage biopharmaceutical company that is focused on enabling patients to fight cancer without the fear or burden of chemotherapy-induced side effects. The company believes selective
Highlights
The EPS is up by 15% year-on-year
Aileron Therapeutics's equity has increased by 11% QoQ
ALRN's quick ratio has soared by 67% QoQ but it has shrunk by 61% YoY
Aileron Therapeutics's net income has decreased by 44% YoY and by 40% from the previous quarter
Key stats
What are the main financial stats of ALRN
Market
Valuations
Earnings
Shares outstanding
21.67M
Market cap
$80.6M
Enterprise value
$58.65M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.8
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$25.22M
EBITDA
-$25.09M
Free cash flow
-$25.65M
Per share
Balance sheet
Liquidity
EPS
-$3.28
Free cash flow per share
-$1.29
Book value per share
$4.68
Revenue per share
$0
TBVPS
$1.2
Total assets
$109.4M
Total liabilities
$8.38M
Debt
$0
Equity
$101.02M
Working capital
$18.22M
Debt to equity
0
Current ratio
4.69
Quick ratio
4.44
Net debt/EBITDA
0.87
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-30.8%
Return on equity
-33.4%
Return on invested capital
N/A
Return on capital employed
-24.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALRN stock price
How has the Aileron Therapeutics stock price performed over time
Intraday
4.35%
1 week
3.05%
1 month
10.71%
1 year
192.91%
YTD
21.97%
QTD
5.08%
Financial performance
How have Aileron Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$25.52M
Net income
-$25.22M
Gross margin
N/A
Net margin
N/A
Aileron Therapeutics's net income has decreased by 44% YoY and by 40% from the previous quarter
The operating income has declined by 40% year-on-year and by 38% since the previous quarter
Growth
What is Aileron Therapeutics's growth rate over time
Valuation
What is Aileron Therapeutics stock price valuation
P/E
N/A
P/B
0.8
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 15% year-on-year
ALRN's P/B is 100% above its last 4 quarters average of 0.4 but 38% below its 5-year quarterly average of 1.3
Aileron Therapeutics's equity has increased by 11% QoQ
Efficiency
How efficient is Aileron Therapeutics business performance
The ROE has soared by 67% YoY
The ROA has soared by 65% YoY
Dividends
What is ALRN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ALRN.
Financial health
How did Aileron Therapeutics financials performed over time
ALRN's quick ratio has soared by 67% QoQ but it has shrunk by 61% YoY
ALRN's current ratio has surged by 66% since the previous quarter but it has dropped by 60% year-on-year
The debt is 100% smaller than the equity
Aileron Therapeutics's equity has increased by 11% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.